Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: Expert Opin Biol Ther. 2010 Feb;10(2):163–178. doi: 10.1517/14712590903431022

Figure 2. Potential mechanisms of tumor cell lysis by monoclonal antibodies.

Figure 2

MoAbs can (1) be conjugated to toxins or radionuclides, (2) recruit effector cells to participate in ADCC or (3) release inflammatory cytokines that contribute to tumor killing, (4) activate complement, (5) interfere with growth factor signaling, or (6) bind anti-idiotype antibodies.